InMode Ltd. (NASDAQ: INMD)

Sector: Healthcare Industry: Medical Devices CIK: 0001742692
Market Cap 867.05 Mn
P/E 9.25
P/S 2.34
Div. Yield 0.00
Add ratio to table...

About

InMode Ltd., a leading global provider of innovative, energy-based, minimally invasive surgical medical treatment solutions, operates in the medical devices industry with the ticker symbol INMD. The company's primary products and services are designed to address three energy-based treatment categories: face and body contouring, medical aesthetics, and women's health. InMode's products utilize medically-accepted RF energy technology, which can penetrate deep into the subdermal fat, allowing for adipose tissue remodeling. The company's proprietary...

Read more

Investment thesis

Bull case

  • InMode’s core technology, Morpheus8, continues to enjoy robust demand within the minimally invasive aesthetic segment, evidenced by a 22% rise in consumables revenue in 2025. This trend indicates that the installed base is generating repeat procedures, a key driver of high margin recurring revenue that can cushion the company against cyclical downturns. Management’s emphasis on product mix evolution—shifting from high‑margin devices to high‑volume consumables—suggests an intentional strategy to lock in long‑term cash flow. The company’s sizeable cash reserves of $555 million provide the flexibility to support marketing and clinical trial spend while maintaining a disciplined share‑repurchase program, enhancing shareholder value.
  • The forthcoming launch of a Korean‑made Pico laser and an Erbium YAG–Morpheus combination platform represents a strategic expansion into high‑penetration, low‑margin laser markets, which historically dominate aesthetic clinics. By acquiring rather than developing these systems, InMode can leverage proven technology while reducing time‑to‑market, thereby capturing early market share before competitors. The company projects these additions to broaden its addressable market size, especially within the “non‑invasive” segment where demand has doubled in 2025, potentially creating new cross‑sell opportunities between RF and laser solutions. Moreover, the company’s plan to introduce two new platforms annually underscores a commitment to staying ahead of clinical trends, which can translate into sustained competitive differentiation.
  • Geographic diversification has strengthened InMode’s revenue base, with European sales accounting for 46% of 2025 revenue and a 15% YoY increase in that region. The company’s move to open direct subsidiaries in Argentina and Thailand, replacing underperforming distributors, demonstrates an aggressive approach to capturing emerging markets while improving gross margins by reducing distributor cuts. Management’s confidence in “encouraging signs” in Europe—namely increased revenue and a softer interest‑rate environment—suggests that demand in this region may rebound faster than in North America, providing a counter‑balance to domestic softness. Coupled with the consolidation of North American operations into a single sales organization, InMode is positioned to optimize sales force productivity and channel management, enhancing sales efficiency.
  • InMode’s gross margin profile remains healthy, with non‑GAAP gross margins hovering around 78% in 2025 and guidance for 2026 at 75–77%. Despite the anticipated margin drag from laser acquisitions and a 15% U.S. import tariff, the company’s high‑margin core product portfolio, including RF platforms, continues to underpin profitability. Management’s disciplined capital allocation—returning $127 million to shareholders and maintaining a $22.7 million operating cash flow—indicates robust free cash flow generation, which can be deployed for R&D, strategic acquisitions, or further share buybacks. This cash generation capability provides a buffer against potential demand contractions and allows InMode to invest in high‑impact clinical trials, such as the dry‑eye bipolar RF indication and women’s health studies, potentially unlocking new revenue streams.
Read more

Bear case

  • Management’s discussion of strategic alternatives reveals a significant uncertainty about the company’s long‑term value proposition. The CEO’s candid admission that the board is considering “strategic alternatives” and that the process is “not fully involved” in the discussions signals a lack of clear direction and could prompt a market sell‑off if investors fear a potential takeover or breakup. The absence of any concrete timeline or evaluation of these alternatives leaves the market without a defined exit strategy, creating a risk that share prices could deteriorate if a more attractive offer emerges from outside parties. This ambiguity, combined with the company’s historical performance decline (a 6% YoY revenue drop in 2025), may erode investor confidence and depress the stock’s valuation multiple.
  • The anticipated margin compression from the new laser launches poses a material risk to profitability. The company explicitly acknowledged that the CO2, Pico, and Erbium YAG lasers will be sourced externally and carry a higher cost of goods sold, exacerbated by a 15% U.S. import tariff. While the management expects gross margins to remain around 75% in 2026, this figure is significantly lower than the 78–79% margins achieved on the core RF platforms. If the laser sales fail to achieve the projected volume, the company could experience a double whammy of higher COGS and lower average selling price, squeezing operating margins further and potentially eroding earnings per share below guidance.
  • Interest‑rate sensitivity is a persistent risk for InMode, as highlighted by the CEO’s observation that leasing rates for capital equipment are a primary driver of sales volumes. The firm relies heavily on leasing programs to finance the purchase of its high‑cost platforms, and any unexpected rebound in interest rates could elevate the effective cost of capital for physicians, dampening demand for new equipment. This sensitivity is amplified by the company’s reliance on a single sales force structure, which may be less adaptable to sudden shifts in consumer willingness to finance procedures. Consequently, a tightening monetary policy could precipitate a sharper decline in new platform deployments, eroding revenue growth and prolonging the “stabilization” year anticipated for 2026.
  • InMode’s expansion into new markets through direct subsidiaries, while potentially lucrative, also introduces significant operational and regulatory complexities. The CEO’s remarks that the company is establishing subsidiaries in Argentina and Thailand “because we were not very happy with these distributors” suggest a reactive, rather than strategic, approach to market entry. Setting up local manufacturing or sales infrastructure requires substantial capital outlays, local talent acquisition, and compliance with diverse regulatory regimes—all of which can erode cash flow and dilute focus from the core business. Furthermore, the company’s distribution network still accounts for 20% of revenue, indicating that the direct sales model has not yet fully supplanted traditional channels, which may limit growth and margin expansion in the near term.
Read more

Product and Service Breakdown of Revenue (2025)

Statement of Income Location, Balance Breakdown of Revenue (2025)

Peer comparison

Companies in the Medical Devices
S.No. Ticker Company Market Cap P/E P/S Total Debt (Qtr)
1 ABT Abbott Laboratories 177.36 Bn 27.31 4.00 12.93 Bn
2 SYK Stryker Corp 124.60 Bn 38.40 4.96 15.86 Bn
3 MDT Medtronic plc 109.93 Bn 23.82 3.10 28.07 Bn
4 BSX Boston Scientific Corp 93.15 Bn 31.94 4.64 11.44 Bn
5 EW Edwards Lifesciences Corp 46.49 Bn 43.68 7.66 0.60 Bn
6 PHG Koninklijke Philips Nv 29.40 Bn 25.00 1.46 9.41 Bn
7 DXCM Dexcom Inc 24.14 Bn 28.78 5.18 -
8 STE STERIS plc 21.56 Bn 30.26 3.70 1.90 Bn